[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528925":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":60,"collaborators":18,"id":63,"slug":18,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":18,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":18,"enrollmentInfo":71,"targetDuration":18,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":18,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Chongqing University Cancer Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Optimized CTV","EXPERIMENTAL","The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.",[13],"Radiation: CTV optimized IMRT",{"label":15,"type":16,"description":17,"interventionNames":18},"Conventional CTV","NO_INTERVENTION","The CTV1 was defined as GTVnx + 5 mm + entire nasopharynx mucosa .The CTV2 was defined as GTV1+ 5 mm + corresponding anatomical structures.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"RADIATION","CTV optimized IMRT","The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as a potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.",[9],[26],{"name":27,"affiliation":5,"role":28},"Ying Wang, Ph.D, M.D.","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Yuwei Wang, M.M.","CONTACT","13436161758","38664816@qq.com",{"name":36,"role":32,"phone":37,"phoneExt":18,"email":38},"Ying Wang, Ph.D,M.D.","13996412826","yingwang197011@163.com",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Chongqing","Chongqing Municipality","400030","China","CN",{"type":48,"coordinates":49},"Point",[50,51],106.55771,29.56026,{"lat":51,"lon":50},[54,55,57,58],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},{"name":56,"role":32,"phone":37,"phoneExt":18,"email":38},"Ying Wang, Ph.D, M. D.",{"name":56,"role":28,"phone":18,"phoneExt":18,"email":18},{"name":31,"role":59,"phone":18,"phoneExt":18,"email":18},"SUB_INVESTIGATOR",{"type":28,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Ying Wang","Associate Director of Chongqing University Cancer Hospital","100528925",false,"NCT06167109","NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma","Endoscopic NBI Combined With MRI to Guide the Optimization of Clinical Target Volume Delineation in Eccentric Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Males and females ≥18 years of age;\n2. ECOG Performance Status 0,1 or 2;\n3. Pathologically diagnosed as nasopharyngeal carcinoma;\n4. Pretreatment nasopharynx and neck MRI imaging;\n5. Nasopharyngeal suspected lesions were examined by NBI endoscopy;\n6. Meeting the definition of eccentric NPC with ipsilateral (affected side) staging of T1-4 and contralateral (healthy side) staging of T0;\n7. Patients evaluated without contraindications to radiotherapy;\n8. Voluntary participation in clinical research, and signed informed consent.\n\nExclusion Criteria:\n\n1. Patients who did not successfully undergo all three examinations (MRI, NBI, and endoscopic biopsy);\n2. Other rare pathological types, such as adenocarcinoma;\n3. Patients with tumor invasion of the clivus;\n4. Patients whose contralateral retropharyngeal lymph nodes met the diagnostic criteria;\n5. Invasion of paranasal sinuses (except simple sphenoid invasion).","ALL","18 Years",{"count":72,"type":73},60,"ESTIMATED","INTERVENTIONAL",[76],"NA","This is a prospective, single-center clinical trial in eccentric nasopharyngeal carcinoma (NPC) patients. The aim of this study is to evaluate the efficacy and safety of NBI combined with MRI-guided optimized CTV compared with conventional CTV, and to compare the radiotherapy-related adverse events and quality of life between the two groups.",[79],"Nasopharyngeal Carcinoma by AJCC V8 Stage","2023-12-04",{"date":82,"type":83},"2023-12-12","ACTUAL",{"date":85,"type":83},"2023-10-20",{"date":87,"type":73},"2026-10",{"name":5,"class":6},1]